Prosecution Insights
Prosecution Insights
Tech Center 1700 • Art Units: 1621 1651 1657 1682 1759
This examiner grants 68% of resolved cases
Robert J. Yamasaki operates in Tech Center 1700 and Art Unit 1621. The examiner has 565 resolved cases in their history. The data shows an allowance rate of 67.6 percent. The median days to allowance for this examiner is 1184, which helps practitioners set expectations for the timeline of applications. This 1184 day duration represents the middle point of the prosecution period from filing to grant for applications in Art Unit 1621.
The interview lift is 43.7 percent. This suggests that interviews are associated with a much higher probability of allowance compared to cases where no interview is held. Given the 565 resolved cases, the 43.7 percent lift is a key metric for practitioners to consider. Using an interview may significantly improve the 67.6 percent allowance rate while navigating the 1184 day median duration for applications assigned to this examiner.
| App # | Title | Status | Assignee |
|---|---|---|---|
| 19459949 | METHODS FOR IMMOBILIZING AND SORTING A CELL USING LIGHT | Non-Final OA | Cellanome, Inc. |
| 17415010 | METHOD OF ENCODING DATA ON A POLYNUCLEOTIDE STRAND | Final Rejection | Oxford Nanopore Technologies PLC |
| 18722445 | A METHOD FOR REDUCING AMMONIA EMISSION OF ANIMALS | Non-Final OA | DSM IP ASSETS B.V. |
| 18833797 | GENETICALLY ENGINEERED BACTERIUM FOR THE PRODUCTION OF 3-HYDROXYBUTYRATE | Non-Final OA | Alliance for Energy Innovation LLC |
| 18288728 | NOVEL PROTEIN HAVING METHANE OR BUTANE OXIDATION ACTIVITY | Final Rejection | KOREA UNIVERSITY RESEARCH AND BUSINESS FOUNDATION |
| 18264843 | METHODS FOR (POLY) PEPTIDE TANDEM LIGATION AND CYCLIZATION | Non-Final OA | Nanyang Technological University |
| 18571661 | RECOMBINANT CUTINASE EXPRESSION | Final Rejection | Novozymes A/S |
| 18732149 | NUCLEOSIDE TRIPHOSPHATE PHOTOAFFINITY PROBE, METHOD FOR PREPARING SAME, AND APPLICATIONS THEREOF | Non-Final OA | SHANDONG UNIVERSITY |
| 17658009 | GENERATION OF CELL-BASED PRODUCTS FOR CONSUMPTION THAT COMPRISE PROTEINS FROM EXOTIC, ENDANGERED, AND EXTINCT SPECIES | Final Rejection | The Upside Group Inc. |
IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.
Build Your Strategy